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Type 2 hereditary hemochromatosis (HH) or juvenile hemochro-
matosis is an early onset, genetically heterogeneous, autosomal
recessive disorder of iron overload. Type 2AHH is caused bymuta-
tions in the recently cloned hemojuvelin gene (HJV; also called
HFE2) (Papanikolaou, G., Samuels, M. E., Ludwig, E. H., Mac-
Donald,M. L., Franchini, P. L., Dube,M. P., Andres, L.,MacFarlane,
J., Sakellaropoulos, N., Politou, M., Nemeth, E., Thompson, J.,
Risler, J. K., Zaborowska, C., Babakaiff, R., Radomski, C. C., Pape,
T. D., Davidas, O., Christakis, J., Brissot, P., Lockitch, G., Ganz, T.,
Hayden, M. R., and Goldberg, Y. P. (2004) Nat. Genet. 36, 77–82),
whereas Type 2B HH is caused by mutations in hepcidin. HJV is
highly expressed in both skeletalmuscle and liver.Mutations inHJV
are implicated in the majority of diagnosed juvenile hemochroma-
tosis patients. In this study, we stably transfected HJV cDNA into
human embryonic kidney 293 cells and characterized the process-
ing of HJV and its effect on iron homeostasis. Our results indicate
that HJV is a glycosylphosphatidylinositol-linked protein and
undergoes a partial autocatalytic cleavage during its intracellular
processing. HJV co-immunoprecipitated with neogenin, a receptor
involved in a variety of cellular signaling processes. It did not inter-
actwith the closely related receptorDCC (deleted inColonCancer).
In addition, the HJV G320V mutant implicated in Type 2A HH did
not co-immunoprecipitate with neogenin. Immunoblot analysis of
ferritin levels and transferrin-55Fe accumulation studies indicated
that the HJV-induced increase in intracellular iron levels in human
embryonic kidney 293 cells is dependent on the presence of neoge-
nin in the cells, thus linking these two proteins to intracellular iron
homeostasis.
Hereditary hemochromatosis (HH)2 includes a heterogeneous group
of inherited iron overload diseases resulting from mutations in at least
the following five genes: HFE, hemojuvelin (HJV; also called HFE2),
hepcidin (HAMP), transferrin receptor-2, and ferroportin (FPN; also
called SLC40A1) (1, 2). Type 1HH, themost common form, is caused by
mutations of theHFE gene and is an late onset, autosomal recessive, low
penetrance iron overload disorder (3). Type 2 HH or juvenile hemo-
chromatosis (JH) is a rare autosomal recessive disease with high pen-
etrance that affects young patients of both sexes and that leads to severe
clinical complications typically in the first and second decades of life (4,
5). JH results from mutations of either the HJV gene (Type 2A) or the
hepcidin gene (Type 2B) in early iron loading with similar serum iron
parameters and distribution of accumulated iron in organs (2, 6). Both
Type 1 HH and JH individuals have increased intestinal absorption and
deposition of iron in vital organs, including the liver, heart, and pan-
creas. However, JH individuals have a higher rate of iron absorption and
a more rapid and severe clinical course with a higher frequency of car-
diomyopathy, diabetes, and hypogonadism (5).
HJV is a newly cloned gene localized on chromosome 1q21 (6). This
region of chromosome 1 was previously linked to JH (7–10). HJV has
five predicted spliced transcripts encoding three different proteins of
426, 313, and 200 amino acids. Northern blot analysis has indicated high
expression in adult and fetal liver, heart, and skeletal muscle with the
full-lengthmRNAas the primary transcript. The encoded protein (HJV)
possesses multiple protein domains, including an N-terminal signal
peptide, an RGD motif, a partial von Willebrand factor D motif, and a
C-terminal transmembrane domain (6). Numerous mutations in HJV
that cause Type 2A HH have been identified. These include missense,
frameshift, and nonsense mutations in either homozygous or com-
pound heterozygous individuals (6, 11–16). Although the amino acid
substitution G320V accounts for about two-thirds of Type 2A HH (6),
the sporadic distribution of these mutations hints that Type 2A HH is
due to the loss ofHJV function. Interestingly, the hepcidin levels in these
patients are found to be consistently depressed, suggesting that HJV
may act as a modulator of hepcidin expression (6). Hepcidin is a small
peptide hormone synthesized predominantly in hepatocytes. It is criti-
cal for the maintenance of body iron homeostasis through down-regu-
lation of the iron exporter FPN in intestinal endothelial cells andmacro-
phages (17–19). Hepcidin expression is highly regulated by body iron
status, hypoxia, and inflammation (20). In contrast, a more recent study
found thatHJVmRNA levels are increased by inflammation, but do not
respond to iron status or erythropoietin in mice (21).
HJV shares considerable sequence similaritywith the newly identified
repulsive guidance molecules (RGMs) (6). In the mouse (m) RGM fam-
ily, there are at least three members, mRGMa, mRGMb, and mRGMc
(22–24). Human HJV is the ortholog of mRGMc (Fig. 1). In situ hybrid-
ization analysis of the distribution of the various RGMs in mouse
embryos has shown that mRGMa and mRGMb are expressed predom-
inantly in distinct, mostly no-overlapping patterns in the developing
and adult central nervous systems, whereas mRGMc is expressed
mainly in skeletal and heart muscles (22–24). The in situ localization of
mRGMc is consistent with the Northern blot analysis results of HJV
mRNA in human tissues and the fact that no neural symptoms have
been reported in Type 2A HH patients (6). Functional studies of
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mRGMa in mouse embryos have revealed that it plays a critical role in
the control of cephalic neural tube closure and formation of afferent
connections in the dentate gyrus (24, 25). Chicken RGM, an ortholog of
mRGMa, has also been reported to be essential for retinotectal map
formation in the chick embryo (26). More recent studies have demon-
strated that neogenin is the high affinity receptor for chicken andmouse
RGMs and that their interaction is critical in the regulation of neuronal
survival (27, 28).
Neogenin is a membrane protein. It is closely related to another
receptor, DCC (deleted in Colon Cancer), with nearly 50% amino acid
identity. Neogenin is widely expressed in different tissues, including
muscles and liver (29–31). Functional studies in zebrafish embryos
using morpholino oligonucleotides demonstrated that it is essential for
neural tube formation and somitogenesis (32), a function similar to
mRGMa in mouse embryos (24). This evidence supports the idea that
the RGMa/neogenin interaction is indispensable for neural develop-
ment. On the basis of the high sequence identity of RGMa to RGMc and
human HJV, the lack of RGMa in the liver, and finally the presence of
HJV and neogenin in the liver (6, 22–24), we speculate that neogenin
might also be a candidate receptor for HJV.
In this study, we stably transfectedHJV cDNA into human embryonic
kidney 293 (HEK293) cells and characterized its effect on iron homeo-
stasis. Our results indicate that HJV is processed similarly to other
members of the RGM family of proteins. Immunoprecipitation analysis
demonstrated that HJV interacts with neogenin, but not with DCC, and
that theHJVG320Vmutant implicated in Type 2AHHdoes not bind to
neogenin. Immunoblot analysis of ferritin levels and transferrin (Tf)-
bound 55Fe accumulation studies showed that the HJV-induced
increases in intracellular iron levels in HEK293 cells are dependent on
the presence of neogenin in the cells.
EXPERIMENTAL PROCEDURES
Subcloning HJV into pcDNA3—The full-length HJV open reading
frame was amplified from a human liver cDNA library by PCR using the
Expand high fidelity PCR system (Roche Applied Science) with primers
5-atgggggagccaggccagtcccctagtcccaggtcctccc-3 (forward) and 5-tta-
ctgaatgcaaagccacagaacaaagagcccagaaagga-3 (reverse). The amplicon
was subsequently cloned into the pGEM-T vector (Promega). After the
sequence was confirmed by sequencing, the HJV open reading frame
was subcloned into the expression vector pcDNA3 (Invitrogen) tomake
the pcDNA3-HJV construct. Tomap the fragmentation pattern of HJV,
we engineered a modified plasmid by addition of a Myc tag at the posi-
tion 3 amino acid after the N-terminal signal peptide sequence. To do
this, two portions of the HJV open reading frame (the first 111 bp at the
5-end and the remaining 1170 bp at the 3-end) were first amplified
separately using the primers for the full-length HJV open reading
frame cloning (described above) as well as the following primers: 5-ctc-
gaggcattgagaatgagcatgtcc-3 (reverse primer for the former) and 5-ct-
cgaggagcagaaactcatctctgaagaggatctgaagatcctccgctgcaatgct-3 (forward
primer for the latter). An XhoI enzyme digestion site was also included
in these primers to ligate the two HJV fragments. The PCR amplicons
were first cloned into the pGEM-T vector, and their sequences and
orientation in the vectors were verified. The 1170-bp 3-portion of HJV
was excised from pGEM-T with XhoI and SphI and subcloned into
pGEM-T containing the 111-bp 5-portion of HJV. The resulting Myc-
HJV in pGEM-T (pGEM-T-Myc-HJV) was subcloned into the expres-
FIGURE 1. Sequences of human HJV and
mRGMc. Human HJV is 88% identical and 92%
similar to mRGMc. Both have a predicted signal
peptide cleavage site (gray arrow), three consen-
sus sequences for N-linked glycosylation (solid
lines), and 12 Cys residues conserved inHJV and all
of the mRGM family proteins (asterisks). Both HJV
and mRGMc have one predicted acid-sensitive
autocatalytic cleavage site (black arrow) and a pre-
dicted GPI-linked site (white arrow). Anti-HJV pep-
tide antibody was generated against the
sequence indicated by the dotted line.
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sion vector pcDNA3 as follows. Both the pGEM-T-Myc-HJV and
pcDNA3 vectors were first linearized by SphI and ApaI digestion,
respectively, followed by treatment with the Klenow fragment (New
England Biolabs Inc.) to make blunt ends. Myc-HJV was then excised
from linearized pGEM-T-Myc-HJV with NotI and ligated with linear-
ized and NotI-digested pcDNA3 to form pcDNA3-Myc-HJV. The con-
struct was verified by sequencing.
The HJV G320V mutant was made using the QuikChangeTM XL
site-directed mutagenesis kit (Stratagene) following the manufacturer’s
instructions. The pcDNA3-HJV construct was used as a template. The
primers used to introduce the mutation were 5-gctctgtgttggggtgtgc-
cctccaagtc-3 (forward) and 5-gacttggagggcacaccccaacacagagc-3
(reverse). The G320V mutation in the resulting construct was con-
firmed by DNA sequencing. No other sequence changes were detected.
The full-length human neogenin cDNA in pcDNA3 was kindly pro-
vided by Dr. Eric R. Fearon (University of Michigan Medical School,
Ann Arbor, MI). The sequence has been published previously (30).
Transfection—HEK293 cells were cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum and 1 mM
pyruvate. All transfections were performed using Lipofectamine rea-
gent (Invitrogen) according to the manufacturer’s instruction. Tran-
siently transfected cells were used in experiments48 h post-transfec-
tion. For stable transfection, transfected cells were selected under 800
g/ml G418. Positive clones were screened by Western blot analysis.
HEK293 cells stably transfected withMyc-HJV, HJVG320V, and empty
vector (pcDNA3) were designatedMyc-HJVHEK293 cells, HJVG320V
HEK293 cells, and control HEK293 cells, respectively. HT29 cells stably
transfected either with DCC (HT29-DCC11) or with empty vector
(HT29-neo) (33) were kindly provided by Dr. Anna Velcich (Monte-
fiore-Einstein Cancer Center, New York).
Generation of Soluble HJV (sHJV) and Anti-HJV Antibody—A con-
struct encoding a soluble portion of HJV (residues 1–401 inclusive of
the HJV signal sequence) with a C-terminal His tag was subcloned into
the baculovirus transfer vector pVL1393 (Pharmingen). sHJV was puri-
fied from the supernatants of baculovirus-infectedHigh5 cells and buff-
er-exchanged to 10 mM Tris (pH 8) and 200 mM NaCl, followed by
nickel-nitrilotriacetic acid Superflow chromatography (Qiagen Inc.).
Protein from an imidazole elution was further purified by gel filtration
chromatography in 20 mM Tris (pH 8) and 300 mM NaCl at 4 °C (34).
sHJVwas used as an antigen to generate polyclonal antiserum in rabbits
(Pocono Rabbit Farm & Laboratory, Inc., Canadensis, PA).
Fluorescence Microscopy Analysis—Two days prior to immunofluo-
rescence analysis, Myc-HJV HEK293, HJV G320VHEK293 and control
HEK293 cells were seeded onto poly-L-lysine-coated coverslips. After
washing with phosphate-buffered saline, cells were fixed with 4%
paraformaldehyde in phosphate-buffered saline for 15 min at room
temperature. The cells were either blocked directly in 10% fetal bovine
serum in phosphate-buffered saline for 1 h at room temperature (non-
permeabilized cells) or treated with 0.2% Triton X-100 in phosphate-
buffered saline for 10 min, followed by blocking (permeabilized cells).
The cells were then incubated either with affinity-purified anti-Myc
monoclonal antibody (for Myc-HJV; a kind gift from Dr. Jan Christian,
Oregon Health & Science University) at 1:20 dilution or with rabbit
anti-HJV serum (for HJV G320V) at 1:400 dilution for 1 h at room
temperature, followed by incubation with either Alexa 594-labeled donkey
anti-mouse (1:500 dilution) or goat anti-rabbit (1:500 dilution) antibody
(Molecular Probes, Inc., Eugene,OR) as the corresponding secondary anti-
body. Cells were mounted with ProLong antifade reagent (Molecular
Probes, Inc.) and imaged using a Nikon fluorescence microscope (60 oil
immersion lens; Meridian Instrument Company, Inc., Kent,WA).
Immunodetection on Western Blots—Cell lysates from HEK293 and
HT29 cells were prepared as described previously (35). Briefly, samples
were subjected to 8 or 12% SDS-PAGE under reducing or nonreducing
conditions as indicated below. After transferring onto nitrocellulose
membrane and blocking with 5% nonfat milk in buffer containing 0.1 M
Tris-HCl, 0.15 M NaCl (pH 7.4), and 0.05% Tween 20, immunoblot
analysis was performed using mouse anti-Myc monoclonal antibody
(1:500 dilution), rabbit anti-HJV peptide antibody (1:1000 dilution; a
kind gift from Dr. Silvia Arber, University of Basel, Basel, Switzerland)
(24), rabbit anti-HJV serum (1:10,000 dilution), sheep anti-human fer-
ritin antibody (1:1000 dilution; The Binding Site, Ltd., Birmingham,
UK), rabbit anti-neogenin antibody H-175 (1:1000 dilution; Santa Cruz
Biotechnology, Inc.), mouse anti-DCC monoclonal antibody (1:100
dilution; Oncogene Research Products), sheep anti-transferrin receptor
(TfR) antibody (1:10,000), or mouse anti--actin monoclonal antibody
(clone AC-15, 1:10,000 dilution; Sigma). Blots were visualized by incu-
bationwith the appropriate horseradish peroxidase-conjugated second-
ary antibody and chemiluminescence (SuperSignal, Pierce). Equal pro-
tein loading in each lane was verified by both Ponceau S staining and
Western blotting for -actin.
Neutralization of pH in the HJV-processing Compartments—Myc-
HJV HEK293 cells (clones 6 and 15) and control HEK293 cells were
incubated overnight in the presence or absence of 25 mM NH4Cl. Cell
lysateswere prepared as described above and subjected to 12%SDS-PAGE.
HJV was detected using anti-HJV peptide antibody at 1:1000 dilution.
Phosphatidylinositol-specific Phospholipase C (PI-PLC) Cleavage of
Cell-surface HJV—Approximately 5  105 intact HEK293 cells tran-
siently transfected with HJV or empty vector were suspended in 0.2 ml
of Dulbecco’s modified Eagle’s medium and incubated in the presence
or absence of PI-PLC (ProZyme, San Leandro, CA) at a concentration of
1 unit/ml for 2 h at 37 °C in 5% CO2 incubator. Cells were separated
from the supernatant by centrifugation at 500  g for 5 min. Both cell
lysates and supernatants were subjected to 8% SDS-PAGE, followed by
immunodetection of HJV using rabbit anti-HJV antibody at 1:10,000
dilution as described under “Immunodetection on Western Blots.”
Immunoprecipitation—Immunoprecipitation was performed as
described previously (36, 37) with some modifications. Briefly, 50 l of
Pansorbin (Calbiochem) was first coated with antibody by incubation
with 2l of either rabbit anti-HJV serumor 2g of rabbit anti-neogenin
antibody in 50l ofNET/Triton buffer (150mMNaCl, 5mMEDTA, and
10 mM Tris (pH 7.4) with 1% Triton X-100) for 50 min at 4 °C. After
removing the unbound antibody by washing with NET/Triton buffer,
pre-absorbed cell lysate as indicated below was added and incubated at
4 °C for 50 min, followed by washing twice with NET/Triton buffer.
Samples were eluted in 100 l of 2 Laemmli buffer (125 mM Tris-HCl
(pH 6.8), 4% SDS, 20% glycerol, and 10% 2-mercaptoethanol) (38) and
subjected to SDS-PAGE on 8% acrylamide gels under reducing condi-
tions. Immunodetection was performed as described above, except that
rabbit TrueBlot (catalog no. 18-8816, eBioscience) at 1:1000 dilution
was used as the secondary antibody. This secondary antibody was used
to immunodetect protein immunoprecipitatedwith rabbit antibodies. It
does not recognize denatured IgG; and thus, no IgG bands were visible
on the immunoblots.
Tf-55Fe Uptake—Steady state levels of Tf-55Fe uptake were measured
as described previously with somemodifications (37). Briefly, Myc-HJV
HEK293 and control HEK293 cells were transiently transfected with
full-length human neogenin cDNA as described above. One day after
transfection, the medium was replaced with fresh complete medium
(Dulbecco’s modified Eagle’s medium plus 10% fetal calf serum and 800
g/ml G418) and 0.5 M Tf-55Fe. Cells were then incubated in an CO2
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incubator for 24 h, followed by acid washing to remove surface-bound
Tf-55Fe. The amount of 55Fe in cells is expressed as pmol of 55Fe/mg of
cellular protein/24 h. In a parallel experiment, the transfection efficiency of
neogenin cDNAwas evaluated by immunofluorescence analysis using rab-
bit anti-neogenin antibody. About 15% of the cells were strongly positive.
Each set of experiments was conducted in quadruplicate.
Real-time PCR—Real-time PCR was performed as described previ-
ously (39, 40). RNA fromMyc-HJV HEK293 and control HEK293 cells
was isolated using the RNeasy RNA isolation kit (Qiagen Inc.). The
message levels of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), DMT1, FPN, ferritin light and heavy chains, TfR1, HJV, and
neogenin were measured. The primer sequences for GAPDH, DMT1,
FPN,TfR1, and ferritin light and heavy chainswere the same as reported
previously (40). The primers for HJV were 5-gttcttgcattgcgcttcct-3
(forward) and 5-gctccttggacacggcat-3 (reverse). The primers for neo-
genin were 5-acagcctccatcgggactcta-3 (forward) and 5-gctactctcg-
gagtcttccaaca-3 (reverse). The results for each gene of interest are
expressed as the amount relative to that of GAPDH in each cell line.
Neogenin Knockdown Using Small Interfering RNA (siRNA)—siRNA
for neogenin (human NEO1) was purchased from Dharmacon RNA
Technologies to knock down the endogenous neogenin in HEK293
cells. siRNA was transfected into the cells using Oligofectamine
(Invitrogen) at a concentration of 100 nM for 48 h following the manu-
facturer’s instruction. Cells were treated with 5 M Tf for 24 h prior to
harvesting to enhance the ferritin signal. The protein levels of neogenin,
ferritin, and HJV were detected byWestern blotting as described above
under “Immunodetection on Western Blots.”
RESULTS
HJV Is a Membrane-associated Protein—Immunofluorescence of
non-permeabilized and permeabilized cells was used to determine the
localization of HJV in cells. In the non-permeabilized cells, Myc-HJV
was evenly distributed on the plasma membrane (Fig. 2A), indicating
that Myc-HJV traffics to the cell surface and is a membrane-associated
protein. In the Triton X-100-permeabilized cells, HJV was also found in
perinuclear organelles within cells (Fig. 2B).
Characterization of HJV Processing in HEK293 Cells and sHJV—Full-
length HJV cDNA encodes a 426-amino acid protein including an
N-terminal signal peptide of 33 amino acids in length. Immunoblot
analysis of Myc-HJV expressed in HEK293 cells using anti-HJV serum
detected three bands migrating at50, 33, and 14 kDa (Fig. 3A) under
denaturing and reducing conditions. Three bands were also detected in
purified preparations of truncated sHJV (Fig. 3A). To characterize the
origin of the bands, two additional antibodies were used. The anti-Myc
antibody detected the 50- and 14-kDa bands, implying that the 14-kDa
protein is a cleavage product containing the N terminus of HJV. When
the same blot was reprobed with an antibody raised against a peptide
corresponding to amino acids 321–335 of HJV (24), an additional band
at 33 kDa was detected (Fig. 3A, dotted arrow). HJV contains three
potential N-linked glycosylation sites and is predicted, based on a con-
sensus sequence proximal to the transmembrane domain and the lack of
a cytoplasmic domain, to be a glycosylphosphatidylinositol (GPI)-linked
protein. Thus, the 50-kDa band ismost likely the full-length protein; the
14-kDa band is the N-terminal portion with a single N-linked glycosy-
lation site; and the 33-kDa band is the C-terminal portion of HJV with
two N-linked glycosylation sites. The sHJV recombinant protein puri-
fied from the supernatant of Sf9 insect cells was also processed similarly
(Fig. 3A).
In contrast to themultiple bands detected under reducing conditions,
when the gels were run under nonreducing conditions, only a single
band was apparent at 45 kDa in HEK293 cells expressing HJV and at
40 kDa for sHJV (Fig. 3B). The mouse family of RGMs has 12 highly
conserved Cys residues in their ectodomains. These Cys residues are
also conserved in HJV. The single bands detected at 45 kDa under non-
reducing conditions inMyc-HJVHEK293 cell extract and at40 kDa in
sHJV are consistent with the joining of the cleaved protein fragments by
disulfide bonds.
Proteolytic Processing of HJV—Examination of the partial von Will-
ebrand factor D domains of HJV and the RGMs revealed sequence sim-
ilarity to a group of proteins that appear to undergo autocatalytic cleav-
age (41). Specifically, the sequence Gly-Asp-Pro-His (present in HJV
and the RGMs) is known to be cleaved in the humanMUC2mucin, the
sialomucin complex, and heavy chain 3 of the pre--inhibitor (41).
Asp–Pro bonds are well known to be labile under strongly acidic (but
non-physiological) conditions. Presumably, the Gly-Asp-Pro-His
sequences in these proteins are naturally cleaved under mildly acidic
conditions due to a specific conformation and/or general acid catalysis.
mRGMa,mRGMb, andmRGMc and chicken RGMhave been observed
to be cleaved at identical sites (24), but the similarity to other proteins
with a Gly-Asp-Pro-His motif has not been noted previously.
In the case of mucin, cleavage was attenuated by neutralizing the pH
within the lumen of the intracellular organelle by NH4Cl (41). To deter-
mine whether the cleavage of HJV is inhibited at higher pH, Myc-HJV
HEK293 cells were treated overnight with 25 mM NH4Cl. Western blot
analysis of HJV under reducing conditions showed that, in comparison
with untreated cells, treatment with NH4Cl significantly decreased the
intensity of the 33-kDa band (Fig. 3C). These results demonstrate that
cleavage was reduced by NH4Cl treatment and, taking the size of the
cleavage products into account, indirectly indicate that cleavage of the
Asp–Pro bond is most likely responsible for generation of the 33- and
14-kDa peptides. Conversely, incubation of purified recombinant sHJV
at pH 5.5 increased cleavage, further supporting the idea that HJV under-
goes partial autocatalytic cleavage (Fig. 3D). When the three potential
N-glycosylation sites are taken into account, themolecularmasses of bands
FIGURE 2. HJV is found both on the cell surface
and in internal compartments. Cells stably
expressingMyc-HJVwere fixedandeither left non-
permeabilized (A) or permeabilized with 0.2% Tri-
ton X-100 (B). Cells were incubated with purified
anti-Myc monoclonal antibody at 1:20 dilution for
1 h at room temperature, followed by incubation
with Alexa 594-labeled donkey anti-mouse anti-
body at 1:500 dilution. Images were taken with a
60 oil immersion lens. Experiments were
repeated three times with consistent results. In all
experiments, HEK293 cells stably transfected with
the pcDNA3 empty vector served as a negative
control. No staining was detected (data not
shown).
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detected by Western blotting match the predicted molecular masses of
fragments generated by cleavage of the Asp–Pro bond.
HJV Is a GPI-linkedMembrane Protein—A sequence proximal to the
transmembrane domain and the lack of a cytoplasmic domain in HJV
predict that HJV is a GPI-linked protein. To verify this, HJV-transfected
HEK293 cells were treated with PI-PLC, an enzyme that specifically
hydrolyzes the phosphodiester bond of phosphatidylinositol to release
the GPI-linked proteins from membranes (42). Treatment of cells with
PI-PLC led to the release of the majority of HJV into the medium (Fig.
3E, lane 6), in agreement with the prediction that it is a GPI-linked
membrane protein. The HJV still remaining cell-associated after PI-
PLC treatment is consistent with the results of immunofluorescence
analysis and reflects an internal pool of HJV. Interestingly, a detectable
amount of HJV was also found in the supernatant from the parallel
control with no PI-PLC addition (Fig. 3E, lane 4), suggesting that HJV
undergoes partial shedding in HEK293 cells. To rule out contaminating
protease activities in the PI-PLC source, TfR, an integral membrane
protein with a protease-sensitive cleavage site in the external domain,
was used as a control. No TfR was detectable in the supernatant of
PI-PLC-treated cells (Fig. 3E). These results indicate that HJV is a GPI-
linked protein.
HJV Expression Increases Ferritin Levels in HJV-transfected HEK293
Cells—Becausemutations inHJV causeType 2AHH,we next examined
the effect of HJV expression on iron homeostasis in Myc-HJV HEK293
cells. The levels of intracellular ferritin, an iron storage protein, were
used as an indicator of cellular iron status. The synthesis of ferritin is
controlled translationally by the binding of iron regulatory proteins to
an iron-responsive element in the 5-untranslated region of its mRNA
(1). In general, increases in ferritin levels reflect increases in intracellular
iron. Two different clones (clones 6 and 15) of cells stably expressing
Myc-HJV (Fig. 4A) were tested for ferritin levels. Because the ferritin
levels are normally low in this cell line, cells were treated either with
physiological levels of human transferrin (5 M holo-Tf) or with 20
g/ml ferric ammonia citrate to increase the basal ferritin levels.
Increases in ferritin levels uponHJV expression became apparent under
these conditions (Fig. 4B). Tf-mediated iron uptake by the cells is
through TfR-mediated endocytosis, whereas the acquisition of iron by
the cells from ferric ammonia citrate is through an undefined pathway.
The higher ferritin levels upon treatment of the cells with either form of
iron suggest that HJV enhances iron accumulation or that it inhibits
iron efflux from these cells.
FIGURE 3. HJV is extensively modified by cleavage, disulfide bond formation, and GPI addition. A, sHJV and cell extracts frommock-transfected control cells (C) and Myc-HJV
HEK293 cells (HJV) were subjected toWestern blotting. Purified sHJV (6 and 20 ng) and cell extracts (50g) were subjected to SDS-PAGE on 12%polyacrylamide gels under reducing
conditions before transfer to nitrocellulose. Blots were probedwith anti-HJV serumgenerated against purified sHJV. Black arrows indicate full-lengthHJV and processed forms in cell
extracts. In the second set of experiments, the first blot was probed with anti-Myc monoclonal antibody and then reprobed with anti-HJV peptide antibody (raised against the
C-terminal region of HJV). The three cleavage products (black arrows) were seen in HEK293 cells expressing full-length Myc-HJV, and the nonspecific band (dotted line) was seen in
untransfected cells. B, Western blots of the same extracts in Awere subjected to nonreducing SDS-PAGE, transferred to nitrocellulose, and probedwith rabbit anti-HJV serum. C, cells
expressing HJV were treated overnight with 25 mM NH4Cl to increase the pH of the HJV-processing compartments before solubilization and then subjected to SDS-PAGE under
reducing conditions and immunoblot analysis of the cleavage products of HJV. Cells transfectedwith empty vectorwere used as a control. Two clonal cell lines (clones 6 and 15)were
tested. In all cases, theblotswereprobedwith rabbit anti-HJVpeptideantibodyat 1:1000dilutionandhorseradishperoxidase-conjugatedgoat anti-rabbit antibodyat 1:5000dilution
and visualized by chemiluminescence. D, shown is the cleavage of purified sHJV. Purified sHJV (7 g) was incubated in either pH 8 or 5.5 buffer for 6 h at 37 °C and subjected to
SDS-PAGE under reducing conditions, and the gels were stained with Coomassie Blue to visualize the protein. E, shown are the phospholipase C cleavage of the GPI linkage and
release of HJV from the cell membrane. Empty vector-transfected cells and HJV-transfected HEK293 cells were treated in the presence (CPI-PLP and HJVPI-PLC, respectively) or
absence (HJV) of PI-PLC in Dulbecco’s modified Eagle’s medium (1 unit/ml) for 2 h at 37 °C in a CO2 incubator, and the cells were pelleted by centrifugation at 500 g for 5 min and
separated from the supernatant (S). Cell lysates were prepared from the pellet (P) using NET/Triton buffer. Samples were subjected to SDS-12% PAGE under reducing conditions
before transfer to nitrocellulose. The blot was cut at the 68-kDa prestained molecular mass marker. The blot was probed with anti-HJV serum at 1:10,000 dilution (upper panel) and
with sheep anti-TfR antibody at 1:10,000 dilution (lower panel). All experiments were repeated at least twice with consistent results.
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Neogenin Expression in Myc-HJV HEK293 Cells Further Enhances
Ferritin Levels—To examine whether neogenin is involved in the HJV-
mediated iron accumulation in HEK293 cells, neogenin was transiently
transfected into bothMyc-HJVHEK293 and control HEK293 cells with
noTf or ferric ammonia citrate supplementation of themedium as extra
iron source. Immunofluorescence analysis of transfected cells using
anti-neogenin antibody revealed that the transfection efficiency was
15% (data not shown). The ferritin levels in these cell lysates were
analyzed by Western blot analysis and compared with the HJV and
neogenin levels (Fig. 5B). Equal protein loading was verified by -actin
detection. Expression of neogenin alone had no effect on ferritin levels,
but expression of both HJV and neogenin together increased ferritin
levels (Fig. 5B, lanes 3 and 4 versus lanes 1 and 2), which was detectable
even without pretreating cells with iron. Interestingly, Western blot
analysis of neogenin indicated that HEK293 cells endogenously express
neogenin and that the levels of endogenously expressedneogenin increased
whenHJVwas expressed (Fig. 5A, lower panel). The fact thatHEK293 cells
express low levels of neogenin explains the increases in iron accumulation
that were observed in cells expressing HJV alone (Fig. 4B).
Expression of HJV and Neogenin in HEK293 Cells Increases 55Fe
Accumulation—To verify that ferritin levels reflect intracellular iron
levels, we also measured the accumulation of 55Fe by overnight incuba-
tion of cells with Tf-55Fe. A modest but significant increase in iron
accumulation (8.9%) was detected in HJV-expressing cells compared
with control cells. When neogenin was transiently cotransfected into
HJV-transfected HEK293 cells, an even greater increase in iron accu-
mulation was observed (18.65% compared with control cells) (Fig. 6). In
agreement with the anti-ferritin Western blot results, expression of
neogenin alone did not show any effect on iron accumulation. These
results again support the involvement of the HJV-neogenin complex in
iron accumulation in HEK293 cells.
HJV Interacts with Neogenin—To explore the mechanism by which
HJV increases iron loading of HEK293 cells, we first examined whether
it interacts with TfR1 by co-immunoprecipitation studies using either
anti-TfR1 or anti-HJV antibody. No complex ofHJVwith TfR1 could be
detected (data not shown). HJV and its ortholog, mRGMc, are closely
related to RGMa, which has been shown to bind to neogenin (22–24, 27,
28). To examine whether HJV also interacts with neogenin, three strat-
egies were used. In the first set of experiments, we tested whether HJV
FIGURE 5. Coexpression of neogenin and HJV in HEK293 cells results in increased
ferritin levels compared with expression of HJV alone. A, cells expressing HJV or
control cells not expressing HJV (C) were transiently transfected with a plasmid coding
for human neogenin. After 48 h, cells were lysed, and extracts (50g of cell lysate) were
subjected to SDS-PAGE under reducing conditions, transferred to nitrocellulose, and
probedwithanti-HJVantibody (solid arrows) andanti-neogeninantibody (dottedarrows)
at 1:500 dilution. The lower panel shows a longer exposure of the neogenin levels in
control cells and HJV-expressing cells. B and C, duplicate gels were probed overnight at
4 °C with sheep anti-human ferritin antibody at 1:1000 dilution or with mouse anti--
actin monoclonal antibody at 1:10,000 dilution as a loading control, respectively. Exper-
iments were repeated four times with consistent results (see the first supplemental fig-
ure for another image).
FIGURE 6. 55Fe accumulation in HEK293 cells. Empty vector-transfected control cells
(C),Myc-HJVHEK293 cells (HJV), cells transiently transfectedwithneogenin (Cneo), and
Myc-HJV HEK293 cells transiently transfectedwith neogenin (HJVneo) were incubated
for 24 h with 0.5 M Tf-55Fe in complete medium in quadruplicate. p values were calcu-
lated using Student’s two-tailed t test. The experiment was repeated with similar results
(see the second supplemental figure).
FIGURE 4.TransfectionofHJV intoHEK293cells results in increased levelsof ferritin
within the cells. Two clonal cell lines (clones 6 and 15) transfected with Myc-HJV were
tested for levels of HJV (A) and ferritin (B) by immunoblot analysis.A, cells expressingHJV
(but not control empty vector-transfected cells (C)) showed full-length HJV and pro-
cessed forms (black arrows). A nonspecific band at43 kDa was evident in both control
and transfected cells. The blot was first probed with anti-Mycmonoclonal antibody and
then reprobed with anti-HJV peptide antibody (raised against the C-terminal region of
HJV). B, ferritin levels were determined in cells grown overnight in medium alone or
supplemented with human Tf (5 M) or with ferric ammonium citrate (FAC; 20 g/ml).
Blots were probed sequentially with sheep anti-human ferritin (Ft) antibody at 1:1000
dilution for 2 h at room temperature and then with horseradish peroxidase-conjugated
goat anti-sheep IgG (Chemicon Australia Pty. Ltd.) at 1:10,000 dilution for 1 h and visu-
alized by chemiluminescence. Experiments were repeated three times with consistent
results.
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interacts with endogenous neogenin in HEK293 cells using polyclonal
antiserum to HJV. Immunoblot analysis indicated that endogenous
neogenin co-immunoprecipitated with HJV (Fig. 7A). In the second set
of experiments, neogenin was transiently transfected into Myc-HJV
HEK293 cells, followed by immunoprecipitation using rabbit anti-HJV
antibody. Neogenin co-immunoprecipitated with Myc-HJV, indicating
that the Myc epitope did not interfere with the interaction (data not
shown). In the third set of experiments, plasmids encoding neogenin
and untagged HJV were transfected into separate batches of HEK293
cells. The solubilized cell lysates from the two populations were mixed
and incubated for 1 h at 4 °C, followed by immunoprecipitation using
anti-HJV antibody. In agreement with the finding in cells coexpressing
Myc-HJV and neogenin, the antibody to HJV co-immunoprecipitated
both HJV and neogenin (Fig. 7B), indicating that the two proteins bind
to each other in solubilized extracts. These results demonstrate that
both untagged HJV and Myc-HJV behave similarly. Thus, the HJV-
neogenin complex has a high enough affinity to survive the rigors of
immunoprecipitation.
HJV G320V Does Not Interact with Neogenin—To further character-
ize the interaction between HJV and neogenin, we examined the effect
of the HJV G320V mutation, the most common mutation in Type 2A
HH patients (6), by co-immunoprecipitation studies. It did not bind to
neogenin in co-immunoprecipitation studies (Fig. 7B), even though
HJVG320V appeared to be properly glycosylated and transported to the
cell surface (Fig. 7C). Because HJV G230V did not bind neogenin, it
failed to stabilize endogenously expressed neogenin and to increase fer-
ritin levels (Fig. 7D). These results provide further support for the
importance of the HJV/neogenin interaction in Type 2A HH.
HJVDoes Not Interact with the Closely Related DCC—We also tested
whetherHJV interacts withDCC, amembrane protein closely related to
neogenin (29–31), by mixing the cell lysate from HEK293 cells tran-
siently transfected with HJV with the lysate from HT29 cells stably
FIGURE 7. Co-immunoprecipitation of neogenin with HJV. A, Myc-HJV coprecipitated with endogenous neogenin in HEK293 cells. Lysates (150 g of protein) from Myc-HJV
HEK293 cells (HJV) and control HEK293 cells (C) were immunoprecipitated using either rabbit anti-HJV serum (HJV) or rabbit anti-neogenin antibody (neo). Immunoprecipitates were
subjected to SDS-PAGE under reducing conditions, transferred to nitrocellulose, and probed with anti-neogenin antibody. B, extracts from control HEK293 cells (C) or HEK293 cells
transiently expressing either wild-type HJV (wt) or HJV G320V (G320V) were mixed with extracts from HEK293 cells transiently transfected with neogenin (wtneo and G320Vneo)
at equal amounts of protein. The mixed extracts (120g of protein) were immunoprecipitated with anti-HJV serum. The extracts (E) and immunoprecipitates (IP) were subjected to
SDS-PAGE under reducing conditions, transferred to nitrocellulose, and probed with anti-HJV antibody to detect HJV (solid arrow). Anti-neogenin antibody was used to detect
neogenin in cell extracts and immunoprecipitates (dotted arrow). C, cell-surface HJV G320V in stably transfected HEK293 cells under non-permeabilized conditions was visualized by
immunofluorescence. Cells were fixed and incubated with rabbit anti-HJV serum at 1:400 dilution for 1 h at room temperature, followed by incubation with Alexa 594-labeled goat
anti-rabbit antibody at 1:500 dilution. Images were taken using a60 oil immersion lens.D, the coexpression of neogenin and HJV G320V in HEK293 cells did not alter ferritin levels.
Cells expressingHJVG320V (G320V) or control cells not expressingHJV (C)were transiently transfectedwith aplasmid coding forhumanneogenin. After 48h, cellswere lysed. Extracts
(50gof protein)were subjected to SDS-PAGEunder reducing conditions; transferred to nitrocellulose; andprobedwith anti-neogenin antibody at 1:500 dilution (dotted arrow) and
anti-HJV, anti--actin, and anti-ferritin antibodies at 1:1000 dilution (solid arrows). The cell lysate from HJV-transfected HEK293 cells was also included as a control. E, extracts from
HT29 cells stably transfectedwith DCC (EDCC) weremixedwith extracts fromHEK293 cells transiently transfectedwith HJV (EHJV) and immunoprecipitatedwith anti-HJV serum.
The extracts (E) and immunoprecipitates (IP) were subjected to SDS-PAGE under reducing conditions, transferred to nitrocellulose, and probedwith anti-HJV antibody to detect HJV
(solid arrow). Anti-DCC antibody was used to detect DCC in cell extracts and immunoprecipitates (dotted arrow). The lower panel is a longer exposure of the upper panel showing no
detectable DCC coprecipitatingwith HJV. The bands on the immunoblot were visualizedwith a horseradish peroxidase-conjugated anti-rabbit antibody that does not recognize the
denatured heavy and light chains of rabbit IgG (eBioscience), followed by chemiluminescence. All experiments were repeated at least twice with consistent results.
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expressing DCC. Immunoprecipitation studies using anti-HJV anti-
serum failed to pull down detectable DCC (Fig. 7E), despite the fact that
both neogenin and DCC share nearly 50% amino acid identity (30).
These results suggest that the interaction between HJV and neogenin is
specific.
HJV Expression Decreases DMT1 and TfR1 mRNA Levels—To gain
insight into how HJV interferes with iron homeostasis through binding
to neogenin in HEK293 cells, we measured the mRNA levels of iron
metabolism-related genes, including DMT1, FPN, TfR1, ferritin light
and heavy chains, HJV, and neogenin, by quantitative real-time reverse
transcription-PCR. ThemRNA levels ofDMT1 and TfR1 in HJV-trans-
fected HEK293 cells were significantly decreased by 30 and 27%,
respectively, in comparisonwith control HEK293 cells. As expression of
these proteins is lowered under conditions of high cellular iron (1), these
results are consistent with the ferritin blot results demonstrating that
HJV expression results in higher iron levels. No significant changes in
either ferritin light or heavy chain mRNA were detected (data not
shown), consistent with the iron-mediated translational control of fer-
ritin levels. Interestingly, the levels of endogenous neogenin mRNA
were comparablewith those ofDMT1mRNAand did not increase upon
HJV expression. Because we observed increased protein levels of neo-
genin in HJV-expressing cells, HJV could either stabilize the neogenin
protein or increase translation of itsmessage. To determinewhether the
HJV/neogenin interaction might affect iron efflux, we checked whether
FPN, an iron exporter, is expressed inHEK293 cells. Detectable levels of
FPN mRNA in HEK293 cells were measured (Fig. 8); thus, the 55Fe
accumulation detected in HJV-neogenin-transfected cells could be due
to either increased iron uptake or decreased iron efflux.
DISCUSSION
Just over 1 year ago, mutations inHJVwere identified as the causative
factor in Type 2 HH (6). This finding was supported by subsequent
studies by several other groups showing numerous additionalmutations
of HJV in JH patients (11–16). In this study, we characterized the proc-
essing of HJV expressed in HEK293 cells and identified a binding inter-
action with neogenin that increases iron accumulation in HEK293 cells.
HJV is a member of the RGM family of proteins (24). Included in this
family is chicken RGM, a homolog of the GPI-linked protein mRGMa
(24, 26). We found that HJV is sensitive to PI-PLC digestion, indicating
that it, too, is a GPI-anchored protein. GPI-anchored proteins can be
shed from the membrane in a soluble form by membrane secretase-like
proteolytic cleavage and/or phospholipase cleavage of the GPI anchor
moiety (43–45). The soluble form can then enter the circulation and
bind distant receptors. mRGMc, the ortholog of HJV, is efficiently shed
from transiently transfected COS-7 cells (24), raising the possibility that
the release of HJV from a tissue such asmusclemight allow it to interact
with a receptor on another tissue such as the liver. We failed to detect any
soluble form of HJV in the conditioned medium from HJV-transfected
HEK293 cells byWestern blotting (data not shown). Thismight be due to a
lack of sensitivity of our anti-HJV antibody or the lack of appropriate
enzymes for cleavage in HEK293 cells. HEK293 cells are derived from the
kidney; the kidney does not showHJVexpressionbyNorthernblot analysis
(6), and we did not detect any endogenous levels of HJV.
In addition to the GPI linkage, HJV undergoes other post-transla-
tional modifications. HJV and the mRGMs possess a Gly-Asp-Pro-His
sequence (6, 24). Previous studies showed that the Asp–Pro bond in this
sequence undergoes partial autocatalytic cleavage at pH 6.0 in the
humanMUC2mucin, the sialomucin complex, and heavy chain 3 of the
pre--inhibitor (41). RGMa is also cleaved at this Asp–Pro bond (24).
Three different antibodies that detect distinct epitopes were used to
characterizeHJVprocessingwithinHEK293 cells.Our results show that
HJV undergoes a similar pattern of processing consistent with cleavage
being at this Asp–Pro bond. A single band detected on nonreducing gels
indicates that the cleaved peptides are linked by disulfide bonds. In
addition, this pattern of cleavage was observed in sHJV generated from
both Sf9 cells and HEK293 cells as well (data not shown). In agreement
with these findings, the Asp–Pro bond in chicken RGMawas also found
to be cleaved in transfected HEK293 cells, although the cleavage
appeared to be more efficient (26). Notably, the cleavage of HJV was
observed inmouse tissues byWestern blot analysis using anti-HJV pep-
tide antibody, which revealed 26- and 30-kDa bands (46). The lack of
full-lengthHJV inmouse tissues (46) implies that it has been either shed
or completely processed at this Asp–Pro bond. The more complete
cleavage detected inmouse tissues comparedwith our findingsmight be
due to tissue-specific processing.
In this study, we found that the function of HJV in the regulation of
iron accumulation depends on its interaction with neogenin in HEK293
cells. Expression of HJV resulted in a modest increase in ferritin levels,
and expression of neogenin enhanced this effect. HJV expression
increased iron accumulation from both Tf and non-Tf iron sources,
whereas neogenin expression alone had no significant effect in HEK293
cells. These latter results suggest that the HJV-neogenin complex is
necessary for iron accumulation within cells. We attempted to knock
down the endogenous neogenin using siRNA to further verify that neo-
genin is responsible for the HJV-induced changes in iron homeostasis.
Treatment of cells with siRNA resulted in only an 40% reduction in
neogenin protein levels, still well above the levels in control HEK293
cells (data not shown). This might be due to the stabilization of neoge-
nin protein by HJV.
The proposal that HJV-induced changes in iron homeostasis require
interaction with neogenin is supported by the observation that the HJV
G320V mutation, the most common mutation in Type 2A HH (6, 14),
neither interacted with neogenin nor altered intracellular iron levels.
Notably, expression ofHJV overlappedwith that of neogenin inmuscles
and liver, but not with expression of two other RGM family members,
RGMa and RGMb (22–24,30). Although neogenin is also a receptor for
netrins, their interactions are involved mainly in neural development
(47–49). For example, in netrin-1-deficient mice, defects include the
aberrant development of hippocampal circuits and altered neural activ-
ity, with no apparent abnormality in iron homeostasis reported (50).
This implies that netrins are not involved in the regulation of iron
metabolism. Human neogenin has two alternatively spliced forms
FIGURE 8. Relative mRNA levels of iron-related proteins. Quantitative reverse tran-
scription-PCR was used to measure relative levels of the mRNAs of interest in mock-
transfected control HEK293 cells (gray bars) and Myc-HJV HEK293 cells (black bars). All
data were derived from three sets of cDNA preparations and were normalized to an
internal standard (GAPDH). All mRNA levels are expressed as a -fold change relative to
GAPDH. p valueswere calculated using Student’s two-tailed t test (HJVmRNA levels: control
HEK293 cells, 0.000049 0.000024;Myc-HJVHEK293 cells, 0.617928 0.041329).
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encoding proteins of 1461 and 1408 amino acid, respectively, with the
deletion of 53 amino acids in the cytoplasmic domain of the latter
including the loss of three potential phosphorylation sites. The common
extracellular portion consists of four immunoglobulin-like and six
fibronectin type III-like domains (30). We speculate that each ligand
binds to a preferential isoform of neogenin, a distinct domain in neoge-
nin, or a combination of both to trigger the corresponding signal trans-
duction pathway in specific target cells resulting in different conse-
quences. More specifically, binding of HJV to neogenin in muscles and
liver would be assumed to activate the signal transduction pathway(s)
involved in the regulation of iron homeostasis. In addition, failure of the
HJV G320V mutant to interact with neogenin and to alter cellular iron
levels also implies that Type 2A JH is due to the loss of HJV function.
The observation that HJV interacts with neogenin opens up the pos-
sibility that HJV stimulates intracellular signaling events. Neogenin is a
transmembrane protein widely expressed in different adult tissues (31).
It is the receptor for a variety of ligands such as RGMa and netrins (27,
28, 48). Neogenin binding to RGMa has two important functions: reg-
ulation of neuronal survival and guidance of axon growth during devel-
opment (27, 28, 51). In the neural tube, RGMa functions as a cell survival
factor by repressing the pro-apoptotic activity of neogenin (28). The
binding of netrins to neogenin is involved in neural development,
although studies have also indicate a role in epithelial morphogenesis
and myotube formation (47–49). Netrins are a small family of secreted
laminin-like proteins originally identified as neuronal guidance cues.
Netrins have at least six different receptors. In addition to neogenin,
netrins also bind to DCC and four UNC5 proteins (UNC5A–D in the
human and UNC5H1–4 in the mouse) (47). In neuronal development,
netrins can either attract or repel axonal projections depending upon
the receptors with which they interact on the neuronal growth cones
(47). In addition, the interaction of netrin-1with its receptors (DCC and
the UNC5 molecules) is implicated in the regulation of apoptosis,
implying an important role in tumorigenesis (52). All these processes
tend to be accomplished through signal transduction pathways (47, 49,
51). The above findings indicate that neogenin has multiple ligands and
exerts different functions based upon its spatial and temporal associa-
tionwith its ligand. This notion is supported by studies of neogenin knock-
out in early zebrafish embryos indicating a role forneogenin indetermining
cell polarity or directionality of migration in both neuroectodermal and
mesodermal cells (32).The fact that neogenin coupleswithdifferent signal-
ing complexes in a cell type- and ligand-specificmanner raises the possibil-
ity that theHJV-neogenin complex could result in a signaling cascade in the
liver, ultimately affecting hepcidin production.
Type 2AHH patients with mutations in HJV have decreased levels of
hepcidin, indicating the involvement of HJV in the regulation of hepci-
din synthesis (6). HJV mRNA levels are highest in skeletal muscle, fol-
lowed by liver and heart (6), whereas hepcidin is expressed predomi-
nantly in hepatocytes (17, 18, 39), with little or no expression in skeletal
muscle.3 Thus, HJV and hepcidin have only a limited overlap in tissue
expression. The liver is a critical organ in the regulation of body iron
homeostasis, important for iron storage and the synthesis of transferrin,
ceruloplasmin, and hepcidin. Skeletal and cardiac muscles require iron
for incorporation into the heme of myoglobin (53). Based on the need
for iron in muscles, the abundance of HJV in muscle, the lack of regu-
lation of HJV at the mRNA levels by iron loading in mice (21), and our
present results, we propose a model by which HJV and neogenin inter-
act to regulate iron homeostasis. In skeletal muscle cells, HJV-neogenin
complex formation regulates intracellular iron levels for incorporation
into the heme of myoglobin. HJV in skeletal muscle is shed and enters
the circulation as a soluble form of HJV. The amount of shedding could
be regulated by iron supply inmuscle, oxygen tension in the circulation,
or other factors. The binding of HJV to neogenin and perhaps other
coreceptors on hepatocytes up-regulates hepcidin mRNA through as
yet unidentified signaling pathways. Lack of functional HJV would
result in low levels of hepcidin and increased iron uptake by the intes-
tines. Full understanding of this pathway is the next challenge.
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